L4545

L-798106

≥98% (HPLC)

• Synonim(y): (2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide
• Wzór empiryczny (zapis Hilla): C₂₇H₂₂BrNO₄S
• Numer CAS: 244101-02-8
• Masa cząsteczkowa: 536.44
• NACRES: NA.77
• PubChem Substance ID: 329817411
• UNSPSC Code: 12352204
• MDL number: MFCD08272644
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• assay: ≥98% (HPLC)
• form: powder
• solubility: DMSO: >20 mg/mL
• originator: Merck & Co., Inc., Kenilworth, NJ, U.S.
• storage temp.: 2-8°C
• SMILES string: COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c2ccccc2Cc3ccc4ccccc4c3
• InChI: 1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+
• InChI key: ODTKFNUPVBULRJ-NTCAYCPXSA-N

Opis

Application

L-798106, a selective prostanoid receptor EP3 antagonist, is used in prostanoid receptor signaling studies that regulate COX-2 levels and the central excitatory effects of PGE(2) on PVN neurons.[1]

Biochem/physiol Actions

L-798106 is a potent, selective prostanoid receptor EP3-selective antagonists.

L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE₂ is due to its prostanoid EP3 agonist activity.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Hazard Classifications: Aquatic Chronic 4
• hcodes: H413
• pcodes: P273 - P501
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable